26
|
Shepherd F. MS21.04 Targeted Therapy - The Second Revolution. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
27
|
Hueniken K, Hurry M, Jiang S, Labbe C, Brown M, Eng L, Naik H, Liang M, Patel D, Bradbury P, Leighl N, Shepherd F, Xu W, O'Kane G, Walton R, Liu G. P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A Real World Assessment. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Sequist L, Gray J, Harb W, Doebele R, Modiano M, Jackman D, Baggstrom M, Atmaca A, Felip E, Provencio M, Cobo Dols M, Adiwijaya B, Kuesters G, Kamoun W, Andreas K, Pipas J, Santillana S, Cho B, Park K, Shepherd F. P1.13-36 Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Sung M, Zer A, Walia P, Khoja L, Maganti M, Labbe C, Shepherd F, Bradbury P, Liu G, Leighl N. P3.04-20 Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1727] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Yu H, Chen Z, Ballman K, Watson M, Govindan R, Beer D, Bueno R, Herman M, Franklin W, Gandara D, Joshi M, Merrick D, Richards W, Rivard C, Shepherd F, Tsao M, Bokhoven A, Harpole D, Hirsch F. P1.04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
31
|
Moghal N, Pham N, Shi R, Radulovich N, Li M, Raghavan V, Li Q, Wang D, Tong J, Zhu C, Li L, Stewart E, Tamblyn L, Weiss J, Martins-Filho S, Ravi D, Pintilie M, Moran M, Liu G, Leighl N, Shepherd F, Tsao M. MTE01.02 Lung Patient Derived Xenograft and Organoid. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Antonia S, Gettinger S, Borghaei H, Goldman J, Brahmer J, Ready N, Gerber D, Chow L, Juergens R, Laurie S, Shepherd F, Li X, Li A, Geese W, Hellmann M. P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.558] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Carcereny E, Felip E, Reck M, Patel J, Heist R, Balmanoukian A, Chow L, Paz-Ares L, Qiu J, Coleman S, Mocci S, Sandler A, Kurata T, Shepherd F. OA 17.02 Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.428] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
34
|
Reck M, Shepherd F, Pérol M, Cappuzzo F, Shih J, Park K, Winfree K, Alexandris E, Lee P, Sashegyi A, Garon E. MA 03.06 Effect of 2L Ramucirumab after Rapid Time to Progression on 1L Therapy: Subgroup Analysis of REVEL in Advanced NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.464] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Hao D, Sengupta A, Ding K, Leighl N, Shepherd F, Seymour L, Weljie A. P2.01-055 Examining Metabolomics as a Prognostic Marker in Metastatic Non–Small Cell Lung Cancer Patients Undergoing First-Line Chemotherapy. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Sequist L, Anderson I, Bauer T, Demars N, Felip E, Frost N, Harb W, Horn L, Huber R, Kudla A, Lee J, Mathews S, Mehra R, Nieva J, Perol M, Shepherd F, Spira A, Czibere A. A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.96] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
Zer A, Hershko-Klement A, Hwang D, Korpanty G, Leighl N, Liu G, Feld R, Burkes R, Tsao M, Shepherd F. 176P: ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30286-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Yau V, Giuliani M, Wong O, Le L, Darling G, Shepherd F, Brade A, Cho J, Sun A, Bezjak A, Hope A. Outcomes in Patients With Stage III Non-Small Cell Lung Cancer Treated With Neoadjuvant Concurrent Chemotherapy and Radiation Therapy Followed by Surgical Resection. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
39
|
Seymour L, Le Teuff G, Tsao M, Brambilla E, Shepherd F, Soria J, Kratzke R, Graziano S, Douillard J, Rosell R, Reiman A, Lacas B, Bourredjem A, Le Chevalier T, Pirker R, Filipits M, Hainaut P, Janne P, Pignon J. Prognostic and Predictive Biomarkers for Act (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-Nsclc): Lace-Bio. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Ellis P, Liu G, Millward M, Perrone F, Shepherd F, Seymour L, Sun S, Cho B, Morabito A, Stockler M, Leighl N, Lee C, Wierzbicki R, Favaretto A, Tsao M, Wilson C, Taylor I, Ding K, Goss G, Bradbury P. The Relationship Between Egfr and Kras Mutation Status and Overall Survival (Os) in the Ncic Ctg Br.26 Randomized Trial of Dacomitinib (D) Versus Placebo (P) in Patients with Previously Treated Non Small Cell Lung Cancer (Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.91] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Darling G, Li F, Patsios D, Massey C, Hope A, Keshavjee S, Waddell T, Bezjak A, Shepherd F, De Perrot M, Pierre A, Yasufuku K, Cypel M. O-033 * PATIENTS WITH STAGE IIIA (N2) NON-SMALL-CELL LUNG CANCER SELECTED FOR NEOADJUVANT CHEMORADIATION AND SURGERY HAVE IMPROVED SURVIVAL COMPARED TO PATIENTS TREATED WITH DEFINITIVE CHEMORADIATION. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu167.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
42
|
Pawel JV, Scagliotti G, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Shepherd F, Spigel D, Hirsh V, Sequist L, Shuster D, Zahir H, Wang Q, Schwartz B, Roemeling RV, Sandler AB. Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC). Pneumologie 2014. [DOI: 10.1055/s-0034-1367776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
43
|
Pawel JV, Jotte R, Spigel DR, Socinski MA, O'Brien MER, Paschold E, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schuette W, Lorigan P, Reck M, Domine M, Shepherd F, McNally R, Renschler M. Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC). Pneumologie 2012. [DOI: 10.1055/s-0032-1302561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Hope A, Giuliani M, Ma C, Bezjak A, Sun A, Brade A, Cho B, Leighl N, Shepherd F, Lindsay P. Dosimetric and Clinical Parameters Contributing to Esophagitis and Radiation Pneumonitis following Treatment for Small-cell Lung Carcinoma. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Vincent MD, Butts C, Seymour L, Ding K, Graham B, Twumasi-Ankrah P, Gandara D, Schiller J, Green M, Shepherd F. Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7501] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7501 Background: JBR.10 was one of a number of phase III trials that established adjuvant cisplatin based chemotherapy as a recommended treatment in completely resected NSCLC . Long-term follow-up of these trials is important to document persistent benefit and potential late toxicities of adjuvant therapy. We report the updated survival data for JBR.10 with more than 9 years median follow up. Methods: Patients with completely resected stage IB (T2N0) or II (T1–2N1) NSCLC were randomized to receive 4 cycles of vinorelbine/cisplatin or observation.. Kaplan-Meier curves were generated for overall (OS) and disease specific survival (DSS). Log-rank test was used to compare survival distribution and to test cause specific hazard. For the competing risk analysis, the Gray test was used to test the difference in cause specific incidences. All efficacy analyses were done on an ITT basis. Results: 482 patients were randomized. Data cut-off for this update was July 2008. Median follow-up is 9.3 years (3.2–13.8 y). 12 patients were lost to follow up, a median 4.9 years from randomization (1.5–12 years). 271 deaths have occurred, 73% due to lung cancer or its treatment. Survival analysis continues to show a benefit for chemotherapy: HR .78 (CI .61-.99, p=.04). The benefit appears to be confined to N1 patients: median OS 6.8 y versus 3.6 y, HR .68 (CI .5-.92, p=.01). N0 patients did not appear to benefit: HR 1.03 (CI .7–1.52, p=.87). Chemotherapy significantly prolonged DSS, HR.73 (CI .55-.97, p=.03) Competing risk analysis showed observation to be associated with significantly higher risk of death from lung cancer (p=.02) with no difference in incidences of death from other causes between arms (p=.62). Conclusions: Prolonged follow-up of patients in the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm. [Table: see text]
Collapse
|
46
|
Goss GD, Addison C, Shepherd F, Seymour L, LeMaitre A, Ding K. TGF-α and amphiregulin levels in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib/placebo in the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.11023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11023 Background: In BR.21, erlotinib prolonged survival of previously treated NSCLC pts. We examined the predictive/ prognostic effects of the EGFR ligands, TGFa and amphiregulin(Am). Methods: Plasma was collected prior to treatment in consenting pts. TGFa and Am were analyzed by ELISA (R&D Systems). Samples were blinded, measured in duplicate and ligand concentrations determined following interpolation of a standard curve generated from known quantities of recombinant proteins. Sensitivity was ∼3pg/ml. Cutoff points for TGFa were <10 (low) and ≥10 (high); for Am <1.5 (low) vs 1.5–10 (intermediate) vs >10 (high). Standard statistical methods were used to correlate biomarker data with baseline characteristics and outcomes. Results: In 731 randomized pts, 539 were evaluable for both markers; there was a significant interaction (p=0.03) between the evaluable and inevaluable cohorts (erlotinib benefit favoring the evaluable cohort); evaluable pts were more likely to be male, > 60 and to have EGFR amplification. Baseline high TGFa was associated with poorer ECOG PS (p=0.03) while high Am was associated with worse PS (p<0.0001), anemia (p<0.0001), non response to prior therapies (p=0.01) and no-prior platinum therapy (p=0.02). Although TGFa was not prognostic for OS (HR=1.0, p=0.99), high Am was (HR: Middle vs low: 0.94, 95% C.I 0.49 -1.81; high vs.low: 2.04, 95% C.I 1.43 - 2.91; p=0.0002). High TGFa was a poor prognostic factor for PFS (HR 1.4, p=0.07) as was elevated Am (HR: Middle vs low: 1.02, 95% C.I 0.56 -1.85; high vs. low: 1.67, 95% C.I 1.19 - 2.35, p=0.01). In multivariate analyses including both ligands, high Am remained prognostic, but neither ligand was predictive. Conclusions: High levels of baseline Am appears to be a poor prognostic factor, while low levels of TGFa showed a trend to predict benefit from erlotinib in univariate analyses. [Table: see text] [Table: see text]
Collapse
|
47
|
Soria J, Felip E, Herbst R, Hannah N, laurie S, Armand J, Shepherd F, Berman D. 392 POSTER A phase I/II multicenter trial of BMS-690514, an ErbB-VEGFR inhibitor, in patients with advanced NSCLC who are erlotinib naive or previously treated with erlotinib. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72326-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
48
|
Brade A, Bezjak A, MacRae R, Laurie S, Pond G, Afinec A, Iscoe N, Shepherd F. Concurrent Pemetrexed/Cisplatin/Radiation for Unresectable Stage IIIA/B Non-Small Cell Lung Cancer: A Phase I/II Study. Int J Radiat Oncol Biol Phys 2007. [DOI: 10.1016/j.ijrobp.2007.07.1698] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
49
|
Brade A, Bezjak A, MacRae R, Laurie S, Pond G, Afinec A, Iscoe N, Shepherd F. 6550 POSTER A phase I study of concurrent pemetrexed/cisplatin/radiation for unresectable stage IIIA/B non-small cell lung cancer. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71378-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
50
|
Shepherd F, Hasan B, Hicks L, Cheung M, Ding K, Leighl N, Winton T, Seymour L. 6516 ORAL Venous thromboembolism (VTE) and non-small cell lung cancer (NSCLC): a pooled analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trials. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71344-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|